MARTIN R FARLOW, MD
Neurology at University Blvd, Indianapolis, IN

2002004, Apr 4, 2002

Jul 5, 2001

09/899478

Michelle Glasky - Irvine CA, US
Debomoy Lahiri - Indianapolis IN, US
Martin Farlow - Indianapolis IN, US

A61K031/522, A61K031/505, A61K031/404

514/263350, 514/263200, 514/256000, 514/414000, 514/415000

A method of increasing the synthesis and/or secretion of synaptophysin comprises administering to a patient with a neurological disease or a patient at risk of developing a neurological disease an effective quantity of a purine derivative or analogue, a tetrahydroindolone derivative or analogue, or a pyrimidine derivative or analogue. If the compound is a purine derivative, the purine moiety can be guanine or hypoxanthine. The neurological disease can be a neurodegenerative disease such as Alzheimer's disease or a neurodevelopmental disorder such as Down's syndrome. Typically, the compound can pass through the blood-brain barrier. The purine moiety can be hypoxanthine or guanine. A particularly preferred purine derivative is N-4-carboxyphenyl-3-(6-oxohydropurin-9-yl) propanamide.

2002004, Apr 4, 2002

Jul 5, 2001

09/899611

Michelle Glasky - Irvine CA, US
Debomoy Lahiri - Indianapolis IN, US
Martin Farlow - Indianapolis IN, US

A61K031/522, A61K031/505, A61K031/404

514/263000, 514/256000, 514/419000

A method of either inhibiting the formation of A or stimulating the formation of sAPP comprises administering to a patient with a neurological disease or a patient at risk of developing a neurological disease an effective quantity of a purine derivative or analogue, a tetrahydroindolone derivative or analogue, or a pyrimidine derivative or analogue. If the compound is a purine derivative, the purine moiety can be guanine or hypoxanthine. The neurological disease can be a neurodegenerative disease such as Alzheimer's disease or a neurodevelopmental disorder such as Down's syndrome. Typically, the compound can pass through the blood-brain barrier. The purine moiety can be hypoxanthine or guanine. A particularly preferred purine derivative is N-4-carboxyphenyl-3-(6-oxohydropurin-9-yl) propanamide.

2002001, Feb 14, 2002

Nov 29, 2000

09/726771

Bernardino Ghetti - Indianapolis IN, US
Maria Spillantini - Cambridge, GB
Jill Murrell - Avon IN, US
Michel Goedert - Cambridge, GB
Martin Farlow - Indianapolis IN, US
Aaron Klug - Cambridge, GB

Advanced Research and Technology

C12Q001/68, G01N033/567, G01N033/53, G01N033/537, G01N033/543

435/006000, 435/007210, 435/007920

The present invention relates generally to methods and compositions for the diagnosis, modeling and treatment of tau-related pathologies. In particular, the present invention shows that mutations in the tau gene lead to neurofibrillary tangle formation. More specifically gene mutations are described that lead to alterations in ratios of tau isoforms are shown to lead to the formation of abnormal tau filaments.

6184435, Feb 6, 2001

Jun 7, 1995

8/475176

Merrill D. Benson - Indianapolis IN
Jill Murrell - Indianapolis IN
Martin Farlow - Indianapolis IN
Bernardino Ghetti - Indianapolis IN

Advanced Research and Technology Institute - Bloomington IN

A01K 67027, A01K 67033, G01N 3300

800 18

Methods for screening for risk of Alzheimer's disease involve assaying for a guanine to thymine substitution at position 1924 of the gene encoding the human amyloid precursor protein. Also described are transgenic non-human mammals, especially transgenic mice, harboring an expressable gene sequence encoding human amyloid precursor protein having a phenyalanine for valine amino acid substitution in the transmembrane domain of the amyloid precursor protein.

2005011, May 26, 2005

Oct 22, 2004

10/971306

Sandeep Gupta - Plainsboro NJ, US
Pradeep Banerjee - Hillsborough NJ, US
Debomoy Lahiri - Indianapolis IN, US
Martin Farlow - Indianapolis IN, US

Forest Laboratories, Inc. - New York NY

A61K031/13

514659000

The invention relates to the use of NMDA receptor antagonists such as 1-aminocyclohexane derivatives to modify deposition of potentially toxic and fibrillogenic Aβ peptides in amyloidopathies. Specifically, the invention relates to the ability of memantine to intervene in the processing of APP and decrease the levels of fibrillogenic Aβ peptides.

5879883, Mar 9, 1999

May 3, 1995

8/434018

Merrill D. Benson - Indianapolis IN
Jill Murrell - Indianapolis IN
Martin Farlow - Indianapolis IN
Bernardino Ghetti - Indianapolis IN

Indiana University Foundation - Bloomington IN

C12Q 168, C12N 1511, C07H 2104

435 6

Method for screening for risk of Alzheimer's disease involve assaying for a guanine to thymine substitution at position 1924 of the gene encoding the human amyloid precursor protein. Also described are transgenic mammals harboring an expressable gene sequence encoding human amyloid precursor protein having a phenyanine for valine amino acid substitution in the transmembrane domain of the amyloid precursor protein.

8575215, Nov 5, 2013

Feb 18, 2010

12/708401

Yangsheng Du - Westfield IN, US
Martin R. Farlow - Indianapolis IN, US
Ruyu Du - Carmel IN, US

A61K 31/235

514544, 514543

A method of treating a neurodegenerative or cardiovascular disorder with a compound of the following formula:.

2003013, Jul 24, 2003

Dec 10, 2002

10/316145

Yansheng Du - Carmel IN, US
Martin Farlow - Indianapolis IN, US
Ruyu Du - Carmel IN, US

A61K031/44, A61K031/277, A61K031/40, A61K031/21, A61K031/16, A61K031/165

514/357000, 514/408000, 514/513000, 514/521000, 514/599000, 514/617000

A method of treating a neurodegenerative or cardiovascular disorder with a compound of the following formula: in which X, Y, A, A, R, and Rare defined herein.